AAV gene therapy (Amicus Therapeutics/University of Pennsylvania)

N/A

Report date: 2025/01/26 15:58:16

Base Information

Drug NameAAV gene therapy (Amicus Therapeutics/University of Pennsylvania)
Drug Alias NameAAV based CDKL5 gene replacement therapy(Amicus/University of Pennsylvania)
ClassificationBiologics
Mechanisms of ActionCyclin-dependent kinase-like 5 stimulants
TargetsCyclin-dependent kinase-like 5
Therapy Area/IndicationsNervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAmicus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmicus Therapeutics IncUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsNervous System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A